Publication:
Transfer of T cells from intranasal ovalbumin-immunized mice ameliorates allergic response in ova-sensitized recipient mice

Simple item page
dc.contributor.authorAKKOÇ, TUNÇ
dc.contributor.authorsAkkoc, Tunc; Eifan, Aarif O.; Aydogan, Metin; Ozkara, Selvinaz; Bahceciler, Nerin N.; Barlan, Isil B.
dc.date.accessioned2022-03-12T17:34:50Z
dc.date.available2022-03-12T17:34:50Z
dc.date.issued2008
dc.description.abstractMucosal immunotherapy is suggested as a treatment strategy for tolerance induction in allergic diseases. The purpose of this study was to determine the effect of transferred splenic T cells from intranasal ovalbumin (OVA)-immunized mice to naive mice before sensitization on its impact of cytokine production and airway histopathology. BALB/c mice in group I received intranasal immunotherapy (days1-6), carboxylfluorescein succinyl ester (CFSE)-labeled splenocytes or splenic T cells were i.v. transferred to naive recipients (group 11) before OVA sensitization. Acute murine asthma model was established by two i.p. OVA injections (days 21 and 28) and seven OVA nebulizations (days 42-48) in groups 1, 11 and III. Groups If[ and IV served as asthma model and control, respectively. CFSE-labeled cells in splenocytes and lymph node lymphocytes, lung histopathology, IL-4, IL-10, and interferon (IFN) gamma cytokines of recipients were analyzed 24 hours after OVA nebulization challenge. CFSE-labeled T cells from group I were detected in spleen and regional lymph nodes of the OVA-sensitized recipients (group 11). Smooth muscle and thickness of airways were less in intranasal OVA immunotherapy and OVA-sensitized recipients when compared with the asthma model (p < 0.05). Area of inflammation was significantly suppressed in OVA-sensitized recipients compared with the asthma model (p < 0.01). IL-10 and IFN-gamma levels in splenocyte supernatants were significantly increased in intranasal immunotherapy and OVA-sensitized recipients compared with asthma model and controls (P < 0.01). IL-4 levels were significantly less in intranasal immunotherapy group and the OVA-sensitized recipient group when compared with asthma the model group (p < 0.05). This study suggests that intranasal immunotherapy with allergens regulates T-cell responses and ameliorates airway histopathology in sensitized mice, hence, encouraging mucosal tolerance induction as a suitable treatment of allergic diseases.
dc.identifier.doi10.2500/aap.2008.29.3106
dc.identifier.issn1088-5412
dc.identifier.pubmed18341761
dc.identifier.urihttps://hdl.handle.net/11424/229079
dc.identifier.wosWOS:000258519000012
dc.language.isoeng
dc.publisherOCEAN SIDE PUBLICATIONS INC
dc.relation.ispartofALLERGY AND ASTHMA PROCEEDINGS
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectallergy
dc.subjectIFN-gamma
dc.subjectIL-10
dc.subjectintranasal immunotherapy
dc.subjectmucosal immunotherapy
dc.subjectmurine
dc.subjectovalbumin
dc.subjectT-helper cells
dc.subjectTH1 cells
dc.subjectTH2 cells
dc.subjectMUCOSAL TOLERANCE INDUCTION
dc.subjectAIRWAY HYPERRESPONSIVENESS
dc.subjectSUBLINGUAL IMMUNOTHERAPY
dc.subjectIN-VIVO
dc.subjectINFLAMMATION
dc.subjectHYPERREACTIVITY
dc.subjectINTERLEUKIN-10
dc.subjectMECHANISMS
dc.subjectCHALLENGE
dc.subjectASTHMA
dc.titleTransfer of T cells from intranasal ovalbumin-immunized mice ameliorates allergic response in ova-sensitized recipient mice
dc.typearticle
dspace.entity.typePublication
local.avesis.idc8f27ec1-4205-4412-8420-8f32ceb32ab0
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages6
oaire.citation.endPage416
oaire.citation.issue4
oaire.citation.startPage411
oaire.citation.titleALLERGY AND ASTHMA PROCEEDINGS
oaire.citation.volume29
relation.isAuthorOfPublicationdde3c531-d82d-492a-96eb-d6724483eaa1
relation.isAuthorOfPublication.latestForDiscoverydde3c531-d82d-492a-96eb-d6724483eaa1

Files

Collections

Research Outputs